An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Thomas Powles, Danielle Carroll, Simon Chowdhury, Gwénaëlle Gravis, Florence Joly, Joan Carles, Aude Fléchon, Pablo Maroto, Daniel P. Petrylak, Frédéric Rolland, Natalie Cook, Arjun Vasant Balar, Srikala S. Sridhar, Matthew D. Galsky, Petros Grivas, Alain Ravaud, Robert J. Jones, Jan Cosaert, Darren Hodgson, Iwanka Kozarewa, Richard Mather, Robert McEwen, Florence Mercier, Dónal Landers